Conference Coverage

Efficacy and Safety of Fidanacogene Elaparvovec in Adults with Moderately Severe or Severe Hemophilia B: Updated Results From the Phase 3 BENEGENE-2 Gene Therapy Trial

Health-related Quality-of-Life Outcomes 4 Years After Treatment with Valoctocogene Roxaparvovec

Efficacy and Safety of Valoctocogene Roxaparvovec 4 Years After Gene Transfer in GENEr8-1

Seven-year follow-up of valoctocogene roxaparvovec gene therapy for haemophilia A

Human liver biopsy analysis reveals lower RNA transcription may contribute to a decline in FVIII levels following AAV5-hFVIII-SQ gene therapy

Stable and durable factor IX (FIX) levels over 4 years after etranacogene dezaparvovec gene therapy administration in a Phase 2b trial in patients with haemophilia B

Health-related Quality of Life in Adults With Hemophilia B After Gene Therapy With Fidanacogene Elaparvovec in the BENEGENE-2 Trial

Safety and efficacy of valoctocogene roxaparvovec in participants with active and prior FVIII inhibitors

A Novel Gene Editing Lexicon Strategy for the Haemophilia Community

A New Tool to Assist in Treatment Selection–The World Federation of Hemophilia (WFH) Shared Decision-making (SDM) Tool

Health-related Quality of Life in Adults With Hemophilia B After Receiving Gene Therapy With Fidanacogene Elaparvovec

Bleeding Outcomes in Participants With Factor VIII Activity

Subcategories

Highlights From the 17th Annual Congress of EAHAD

Highlights From the 65th ASH Annual Meeting and Exposition

Highlights From the ESGCT 30th Annual Congress

Highlights From the 31st Congress of ISTH

Highlights From the 32nd Congress of ISTH

Back To Top
Image

About

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics

Essential SSL